{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:48:29Z","timestamp":1793760509515,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12325-024-02948-0","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:03:51Z","timestamp":1723003431000},"page":"3706-3721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor"],"prefix":"10.1007","volume":"41","author":[{"given":"Roberto","family":"Caporali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Kadakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"10055","key":"2948_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"key":"2948_CR2","volume-title":"Rheumatoid arthritis","author":"K Chauhan","year":"2023","unstructured":"Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid arthritis. Treasure Island (FL): StatPearls; 2023."},{"issue":"1","key":"2948_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000935","volume":"5","author":"B Mehta","year":"2019","unstructured":"Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1):e000935.","journal-title":"RMD Open"},{"issue":"6","key":"2948_CR4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"D Solomon","year":"2015","unstructured":"Solomon D, Reed G, Kremer J, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449\u201355.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2948_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/rheumatology\/keq327","volume":"50","author":"J Kekow","year":"2011","unstructured":"Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology. 2011;50(2):401\u20139.","journal-title":"Rheumatology"},{"issue":"1","key":"2948_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase\u00a03b, multicentre, randomised, active-controlled AVERT study of 24\u00a0months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2948_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4491","volume":"16","author":"H Radner","year":"2014","unstructured":"Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):1\u201310.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2948_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/acr.22678","volume":"68","author":"E Alemao","year":"2016","unstructured":"Alemao E, Joo S, Kawabata H, et al. Effects of achieving target measures in rheumatoid arthritis on functional status, quality of life, and resource utilization: analysis of clinical practice data. Arthritis Care Res (Hoboken). 2016;68(3):308\u201317.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2948_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-021-01946-w","volume":"39","author":"AJ Ostor","year":"2022","unstructured":"Ostor AJ, Sawant R, Qi CZ, Wu A, Nagy O, Betts KA. Value of remission in patients with rheumatoid arthritis: a targeted review. Adv Ther. 2022;39:1\u201319.","journal-title":"Adv Ther"},{"issue":"5","key":"2948_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40744-022-00473-6","volume":"9","author":"JR Curtis","year":"2022","unstructured":"Curtis JR, Fox KM, Xie F, et al. The economic benefit of remission for patients with rheumatoid arthritis. Rheumatol Ther. 2022;9(5):1329\u201345.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"2948_CR11","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1080\/03007995.2021.1981278","volume":"37","author":"G Gauthier","year":"2021","unstructured":"Gauthier G, Levin R, Vekeman F, Reyes JM, Chiarello E, Ponce de Leon D. Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis. Curr Med Res Opin. 2021;37(12):2185\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2948_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"2948_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry. Rheumatol Ther. 2017;4:489\u2013502.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"2948_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18(12): 102398.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2948_CR15","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology. 2016;55(3):523\u201334.","journal-title":"Rheumatology"},{"issue":"7","key":"2948_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"2948_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221114101","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022. https:\/\/doi.org\/10.1177\/1759720X221114101.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"2948_CR18","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","volume":"38","author":"KJ Johnson","year":"2019","unstructured":"Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. 2019;38(11):2967\u201376.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"2948_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/acr.23859","volume":"72","author":"AR Karpes Matusevich","year":"2020","unstructured":"Karpes Matusevich AR, Suarez-Almazor ME, Cantor SB, Lal LS, Swint JM, Lopez-Olivo MA. Systematic review of economic evaluations of cycling versus swapping medications in patients with rheumatoid arthritis after failure to respond to tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken). 2020;72(3):343\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2948_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211002682","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021. https:\/\/doi.org\/10.1177\/1759720X211002682.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2948_CR21","unstructured":"AbbVie. AbbVie receives FDA approval of RINVOQ\u2122 (upadacitinib), an oral jak inhibitor for the treatment of moderate to severe rheumatoid arthritis [press release]. 2019. https:\/\/news.abbvie.com\/alert-topics\/immunology\/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.html. Accessed Aug 16, 2023."},{"key":"2948_CR22","unstructured":"European Medicines Agency. Rinvoq. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq. Accessed Feb 13, 2023."},{"issue":"4","key":"2948_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/ijr.15.24","volume":"10","author":"T Koike","year":"2015","unstructured":"Koike T, Inui K. How can the treatment of rheumatoid arthritis be improved in Japan? Int J Clin Rheumtol. 2015;10(4):235\u201345.","journal-title":"Int J Clin Rheumtol"},{"issue":"11","key":"2948_CR24","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"2948_CR25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy JD, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"2948_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"S Babineaux","year":"2016","unstructured":"Babineaux S, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"2948_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabet Metab Syndr Obes Targets Ther. 2016;9:371\u201380.","journal-title":"Diabet Metab Syndr Obes Targets Ther"},{"key":"2948_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","volume":"44","author":"K Yamaoka","year":"2021","unstructured":"Yamaoka K, Tanaka Y, Kameda H, et al. The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan. Drug Saf. 2021;44:711\u201322.","journal-title":"Drug Saf"},{"key":"2948_CR29","unstructured":"AbbVie. AbbVie receives health Canada approval of RINVOQ\u00ae (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis [press release]. https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/press-releases\/Rinvoq-press-release-EN_FINAL.pdf. Accessed Feb\u00a013, 2023."},{"issue":"1","key":"2948_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-022-02744-7","volume":"24","author":"S Ochi","year":"2022","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):1\u201313.","journal-title":"Arthritis Res Ther"},{"key":"2948_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221091450","author":"D-J Park","year":"2022","unstructured":"Park D-J, Choi S-E, Kang J-H, Shin K, Sung Y-K, Lee S-S. Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure. Ther Adv Musculoskelet Dis. 2022. https:\/\/doi.org\/10.1177\/1759720X221091450.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"2948_CR32","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"J-E Gottenberg","year":"2016","unstructured":"Gottenberg J-E, Brocq O, Perdriger A, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172\u201380.","journal-title":"JAMA"},{"issue":"1","key":"2948_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semarthrit.2018.12.006","volume":"49","author":"I Scott","year":"2019","unstructured":"Scott I, Ibrahim F, Panayi G, et al. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life. Semin Arthritis Rheum. 2019;49(1):20\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"2948_CR34","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s10067-019-04600-7","volume":"38","author":"PM Ten Klooster","year":"2019","unstructured":"Ten Klooster PM, Oude Voshaar MA, Fakhouri W, de la Torre I, Nicolay C, van de Laar MA. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy. Clin Rheumatol. 2019;38:2727\u201336.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"2948_CR35","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3899\/jrheum.161404","volume":"44","author":"D Kim","year":"2017","unstructured":"Kim D, Kaneko Y, Takeuchi T. Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis. J Rheumatol. 2017;44(8):1112\u20137.","journal-title":"J Rheumatol"},{"key":"2948_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/BTT.S252575","volume":"15","author":"KE Findeisen","year":"2021","unstructured":"Findeisen KE, Sewell J, Ostor AJ. Biological therapies for rheumatoid arthritis: an overview for the clinician. Biol Targets Ther. 2021;15:343\u201352.","journal-title":"Biol Targets Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02948-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:41:55Z","timestamp":1724755315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02948-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02948-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Roberto Caporali has received speaker and\/or consultant fees from AbbVie, Accord, Celltrion, Eli Lilly, Fresenius, Galapagos, Janssen, MSD, Novartis, Pfizer Inc, and UCB. Peter C. Taylor has received grant and\/or research support from Galapagos and has acted as a consultant for AbbVie, Biogen, Eli Lilly, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Sanofi, and UCB. Jayesh Patel, Aditi Kadakia, and Sander Strengholt are employees of AbbVie Inc and may own stock. Oliver Howell, Jack Milligan, and Sophie Barlow are employees of Adelphi Real World, who acted as consultants to AbbVie for this analysis and have no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines, and therefore it does not require ethics committee approval. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}